HCV NS5B Polymerase Inhibitors for Sustained Viral Load Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Hepatitis C virus (HCV) infection, particularly those involving combinations of pegylated alpha-interferon and ribavirin, do not achieve sustained viral load reduction in a substantial fraction of patients, highlighting a need for more effective therapeutic options.
Innovation Solution
Development of specific compounds, such as those described by the formula I, which demonstrate activity against the HCV NS5B protein, potentially used in conjunction with other anti-HCV agents like interferons or cyclosporin, to inhibit viral replication and protein function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pegylated alpha-interferon and ribavirin are used as combination therapy, then initial viral load reduction is achieved, but sustained viral load reduction is not achieved in a substantial fraction of patients
Solution Approach 1:
The patent modifies the molecular structure of NS5B polymerase inhibitors by changing chemical parameters (introducing specific substituents at defined positions) to optimize binding affinity and inhibitory activity. This structural parameter change enables the compound to achieve sustained viral load reduction, resolving the contradiction between initial response and sustained efficacy.
Solution Approach 2:
The invention employs composite molecular structures combining multiple functional moieties (hydrophobic regions, hydrogen bonding groups, and specific substituent patterns) within a single compound molecule. This composite design enhances the compound's ability to maintain sustained viral load reduction while improving overall treatment efficacy.
2Reliability
If existing HCV therapies are used, then some viral reduction is achieved, but a substantial fraction of patients do not have sustained reduction in viral load
Solution Approach 1:
The compound performs preliminary inhibition of NS5B polymerase activity before viral replication can proceed. By establishing this anti-action early in the replication cycle, the compound prevents sustained viral load reduction from occurring, thereby resolving the contradiction between achieving viral reduction and maintaining it over time.
Solution Approach 2:
The NS5B polymerase inhibitor acts as an intermediary that blocks the critical replication step. This intermediary action prevents the virus from generating new viral particles, thereby eliminating the harmful effect of sustained viral replication while maintaining reliable viral load reduction.
Data Source
AI summary
The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.